Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.60 |
| ▸ | ABL1 | P00519 | 4/20 | 0.59 |
| ▸ | SRC | P12931 | 4/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.59 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.59 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.59 |
| ▸ | BMX | P51813 | 3/20 | 0.58 |
| ▸ | KIT | P10721 | 3/20 | 0.58 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12432525 | 0.94 | LCK (0.61) | BRAFSRCMAPK14BMXKIT | |
| SCHEMBL2311108 | 0.91 | BRAF (0.60) | BRAFABL1SRCMAPK14DDR1 | |
| SCHEMBL2312901 | 0.90 | BRAF (0.63) | BRAFABL1SRCMAPK14DDR1 | |
| SCHEMBL12433873 | 0.90 | BTK (0.58) | BRAFABL1SRCMAPK14KIT | |
| SCHEMBL2313222 | 0.89 | CSF1R (0.66) | BRAFABL1SRCMAPK14DDR1 | |
| SCHEMBL2315865 | 0.89 | BRAF (0.57) | BRAFABL1SRCMAPK14DDR1 | |
| SCHEMBL2318954 | 0.89 | BRAF (0.63) | BRAFABL1SRCMAPK14DDR1 | |
| SCHEMBL12433877 | 0.89 | BRAF (0.55) | BRAFABL1SRCMAPK14KIT | |
| SCHEMBL2359154 | 0.85 | LCK (0.58) | BRAFSRCMAPK14KITCSF1R | |
| SCHEMBL20186950 | 0.85 | BMX (0.61) | BRAFABL1SRCMAPK14DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | claimed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | claimed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | claimed |
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | disclosed |
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| WO-2011093684-A2 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | CDK2, TK1, DTYMK | BRAF 60/4885ABL1 149/4885SRC 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.